Akebia Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Akebia Therapeutics Inc Unternehmen

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Akebia Therapeutics Inc Informationen



BörsenkürzelAKBA

Name des UnternehmensAkebia Therapeutics Inc

IPO-datumMar 20, 2014

CEOMr. John P. Butler

Anzahl der mitarbeiter181

WertpapierartOrdinary Share

GeschäftsjahresendeMar 20

Addresse245 First Street

StadtCAMBRIDGE

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl02142

Telefon16178712098

Websitehttps://akebia.com/

BörsenkürzelAKBA

IPO-datumMar 20, 2014

CEOMr. John P. Butler

Führungskräfte von Akebia Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

--

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Tue, Aug 19

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.84%

State Street Investment Management (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

Andere

80.43%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.84%

State Street Investment Management (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

Andere

80.43%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

17.20%

Investment Advisor/Hedge Fund

13.14%

Hedge Fund

7.04%

Research Firm

4.02%

Individual Investor

3.57%

Private Equity

2.17%

Bank and Trust

0.20%

Pension Fund

0.16%

Venture Capital

0.06%

Andere

52.45%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

299

117.08M

44.16%

+9.43M

2025Q2

284

112.41M

42.78%

+33.09M

2025Q1

280

111.54M

42.50%

+30.68M

2024Q4

258

78.54M

36.08%

+7.41M

2024Q3

257

64.16M

30.51%

-2.18M

2024Q2

248

61.31M

29.27%

-7.52M

2024Q1

290

61.37M

29.36%

-12.30M

2023Q4

289

58.79M

31.24%

-20.79M

2023Q3

300

57.28M

30.45%

-25.18M

2023Q2

308

56.18M

30.22%

-26.52M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

16.58M

6.25%

+2.61M

+18.71%

Jun 30, 2025

The Vanguard Group, Inc.

14.61M

5.51%

+1.93M

+15.18%

Jun 30, 2025

State Street Investment Management (US)

8.00M

3.02%

+1.19M

+17.50%

Jun 30, 2025

Geode Capital Management, L.L.C.

6.07M

2.29%

+1.04M

+20.75%

Jun 30, 2025

Alerce Investment Management, L.P.

5.75M

2.17%

--

Dec 31, 2024

Satter Muneer A

5.75M

2.17%

+5.75M

--

Dec 31, 2024

Morgan Stanley & Co. LLC

4.34M

1.64%

+2.26M

+108.33%

Jun 30, 2025

Renaissance Technologies LLC

4.19M

1.58%

+188.60K

+4.71%

Jun 30, 2025

Goldman Sachs & Company, Inc.

3.53M

1.33%

+1.07M

+43.71%

Jun 30, 2025

MPM BioImpact LLC

2.89M

1.09%

+2.89M

--

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Invesco Biotechnology & Genome ETF

2.36%

Invesco NASDAQ Future Gen 200 ETF

0.42%

ALPS Medical Breakthroughs ETF

0.42%

SPDR S&P Biotech ETF

0.34%

Federated Hermes MDT Small Cap Core ETF

0.2%

Direxion Daily S&P Biotech Bull 3X Shares

0.18%

iShares Micro-Cap ETF

0.13%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Fidelity Enhanced Small Cap ETF

0.09%

Invesco Biotechnology & Genome ETF

Anteil2.36%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.42%

ALPS Medical Breakthroughs ETF

Anteil0.42%

SPDR S&P Biotech ETF

Anteil0.34%

Federated Hermes MDT Small Cap Core ETF

Anteil0.2%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.18%

iShares Micro-Cap ETF

Anteil0.13%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Anteil0.11%

Vanguard US Momentum Factor ETF

Anteil0.1%

Fidelity Enhanced Small Cap ETF

Anteil0.09%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten